Irish companies to take part in 'X-Factor' competition

Four Irish companies will compete internationally at the Thistle BioScience “Rising Stars Showcase”in Edinburgh on Wednesday, February 6.

Four Irish companies will compete internationally at the Thistle BioScience “Rising Stars Showcase" in Edinburgh on Wednesday, February 6.

Companies from Scotland, Israel and for the first time, Ireland will pitch their company to a panel of experts and an audience. The experts provide feedback to each company before a winner is announced.

Competing companies benefit from increased exposure, which will help crucial export markets. Last year’s winner Haptogen, Aberdeen, was subsequently acquired by Wyeth.

All four companies are members of IBEC’s Irish BioIndustry Association (IBIA), the leading representative body for the biotechnology industry in Ireland.

The four competing companies are; BiancaMed, NovaUCD in Dublin, Celtic Catalysts, NovaUCD, Dublin, EnBIO, Rubicon Centre, CIT, Cork and Luxcel BioSciences, BioInnovation Centre, UCC, Cork.

All four companies are working on pioneering technologies, which will ultimately improve the health and well-being of people around the world.

Nova has a long track record in company commercialisation; notable successes include the development and licensing of a BSE test, which has to date generated €2 million in royalty income for UCD and the establishment of a range of successful spin-out companies.

Eleanor Garvey, chair of IBIA and Site Leader in Pfizer Ireland, Dun Laoghaire said: “It is very encouraging to see Irish companies compete internationally in a competition of this calibre. Ireland continues to punch well above its weight at a global level and it is important that indigenous Irish companies have the necessary supports to fully develop their commercial potential.”

More in this section

Lunchtime News Wrap

A lunchtime summary of content highlights on the Irish Examiner website. Delivered at 1pm each day.

Sign up

Our Covid-free newsletter brings together some of the best bits from, as chosen by our editor, direct to your inbox every Monday.

Sign up